Women of Wearables (wearables, health tech & femtech)’s Post

🔬 Lindus Health introduces contract research organisation (CRO) and technology solutions for clinical trials in women’s health To date, the company has enrolled over 2,500 patients in women’s health clinical trials across the US, UK, and Europe. They provide companies developing treatments and diagnostics for women’s health conditions with everything needed to manage their trials end-to-end, covering a wide range of indications such as pregnancy, postpartum depression, ovarian cancer, sexually transmitted infections (STIs), and more. 💬 Emma Ogburn (PhD), Vice President of Clinical Operations of Lindus Health, said: “Women have historically been underrepresented in clinical research, resulting in significant treatment disparities. Here at Lindus, it’s paramount that we help sponsors develop safe and reliable therapies for women by enrolling diverse, representative study populations while taking into account the unique aspects of their biology.” Read more: https://lnkd.in/eG6MVcWT #womenshealth #clinicaltrials #research #genderhealthgap #gendergap #innovation #femtech #womenshealthmatters #science #healthcare

Excited to share such excellent news from the team at NX PRENATAL INC., congratulations!! Here is your ultimate business case, where investment impacts healthcare for the benefit of women's health! "The new data, which represents the largest clinical validation study to date for a Pre Term Birth (PTB) test, substantiated that women with a high-risk test result demonstrated a 20-fold higher risk of pre-term birth than women in the low-risk category. This data validates that NX Prenatal’s sPTB test can be highly effective at stratifying first-trimester pregnancies into risk categories to assist physicians in guiding the appropriate prenatal care." Full commentary here: https://lnkd.in/eTV5xudS Solas BioVentures

#Bikinimedicine If you’ve not heard of this term before - it’s time to educate yourself. (See post below) You can also find out how it applies to cardiovascular disease in-The Exquiste Machine; the new science of the heart Written by my long term colleague and friend Prof Sian Harding #bikinimedicine

Gaining focus and improvement of Women's health issues continues to be an issue worldwide. C2-Ai solutions for supporting delivery of care for expectant mothers is acknowledged here as being a major innovation for enabling safer care and better outcomes for mothers and babies. #womenshealth #healthequity #maternitycare #neonatalcare #healthtech

I had never heard the term #bikinimedicine until I attended my first Women in Pharma (WiP) event back in January. That's where I also heard Professor Sian Harding sharing the startling yet irrefutable evidence around gender bias in cardiac illness. This is not a Women's Health issue- this is an everybody issue. This is not a topic I have chosen to raise at the Women's Health Summit on the 4th June. We don't need to preach to the converted. We need to raise this as a systemic issue which has its roots in complex institutional, research, HCP and even pharmacological differences and bias. That is why I have selected Professor Harding to be the keynote speaker at the i2i CVD Summit on the 12th June. Title: WHY GENDER IS AT THE HEART OF THE MATTER FOR CVD OUTCOMES Since Sian is a Pharmacologist (PhD) by background, she is excited to share fascinating evidence on clinical pharmacological differences in #heartfailure and other cardiovascular areas. She will cover data on hormonal changes and their link to CVD through the lifecycle- from pregnancy to menopause and even in the transgender community. I have told Sian that there is no need to dumb her talk down, since this audience of #GPPharmacists #ClinicalPharmacists will relish this sort of complex and clinical data. What I promise you is this: This session will leave you both educated and activated (and possibly slightly outraged)to challenge this status quo and recognise the importance of gendered medicine in your clinical practice- particulalry in CVD management.   Here's a few startling facts 💔 Women are 50% more likely to receive an incorrect initial diagnosis during a heart attack, increasing their risk of death by 70% 💔 Cardiovascular disease is the leading cause of death for women, responsible for 1 in 3 deaths each year—more than all cancers combined. Yet, only 44% of women recognise it as their greatest health threat   💔 The gender of the HCP you see can radically affect your outcomes, whether you receive the gold standard of care and even survival rates in cardiac illness.   There are only limited spaces, so if you are a GP Clinical Pharmacist, book now for this free i2i Cardiovascular Disease Clinical Summit. Check out the other awesome speakers- there's not just one Professor, but two! Prof. Raj Thakkar Helen Williams Rachana Bhatt Moudy Khodadi Date: 12th June, 2024 Location: Royal Society of Medicine, London 🔗 Register here: https://buff.ly/4aUI5Tb   In case you are still wondering... #BikiniMedicine is the mistaken belief that women’s health only differs from men’s in the parts of the body that a bikini would cover. Thank you for introducing this concept and Professor Harding to me Sarah Sowerby Miriam Kenrick . This is one of the ways I see that I can play my part in the manifesto for acknowledging the need for gendered medicine 💊 #beyondbikinimedicine

#Researchers have developed a groundbreaking #AImodel capable of accurately assessing maternal risk in #pregnant women diagnosed with pre-eclampsia, potentially offering a lifeline in the fight against this life-threatening condition. The study, involving over 8,800 women across 11 countries, has yielded a risk-prediction model that swiftly classifies the severity of pre-eclampsia-related #complications into five distinct categories within just two days of initial assessment. Pre-eclampsia, affecting between 2 to 4 percent of pregnancies worldwide, stands as a significant contributor to #maternal morbidity and mortality, resulting in an alarming number of maternal and newborn deaths #annually, particularly in low- and middle-income countries. While most cases of pre-eclampsia are mild and resolve postpartum, approximately one in ten women in the UK face severe complications, including life-threatening #conditions such as stroke. Named PIERS-ML (Pre-eclampsia Integrated Estimate of Risk – Machine Learning), the newly developed model integrates Machine Learning, a subset of #ArtificialIntelligence, to enhance predictive accuracy. The collaborative efforts of researchers from the University of Strathclyde in Glasgow and King’s College London have culminated in the creation of a versatile tool intended for #international application. With plans underway to develop a user-friendly app for #personalized risk assessment post-diagnosis, the model promises to revolutionize #clinical decision-making and improve patient outcomes. Lead author Tunde Csobán emphasizes the urgency of effective risk assessment in managing pre-eclampsia complications, underscoring the potential of the model to save lives. Kim Cavanagh, a co-author of the paper, highlights the model's adaptability to diverse clinical settings, offering tailored risk predictions aligned with individual patient circumstances. Professor Peter von Dadelszen, the project's Principal Investigator, underscores the model's global relevance and its ability to dynamically adjust based on geographic and socioeconomic factors. The incorporation of variables such as countries’ GDPs and maternal mortality ratios enhances the model's applicability across various healthcare contexts. The #study's comprehensive validation process, involving over 8,800 women from diverse geographical #locations, affirms the model's robustness and reliability. External validation exercises further validate its performance, solidifying its status as a #pioneering tool in pre-eclampsia #risk assessment. Funded through #STRADDLE (Strathclyde Diversity in Data Linkage), Tunde Csobán's PhD research has been instrumental in advancing this groundbreaking initiative, underlining the vital role of interdisciplinary collaboration in driving innovation in #healthcare. #News #Medlr #Healthcare #Health

🌟 Unlock the Diagnostic Power of Saliva! 🌟 On August 6th, we hosted an incredible webinar with Dr. Bonni Goldstein titled "Medicinal Cannabis and Autism: New Horizons in Paediatric Care." Participants gained invaluable insights, including the diagnostic potential of saliva. Saliva is more than just a fluid in your mouth—it’s a powerful diagnostic tool. It's non-invasive, cost-effective, and easy to collect, making it an ideal medium for identifying biomarkers. These biomarkers can provide valuable insights into health conditions, including autism spectrum disorder (ASD). Did you know? Recent studies have shown how salivary metabolites shift towards physiological norms with personalized medical cannabis treatment, correlating with behavioral improvements in children with ASD. This innovative approach is paving the way for more effective and personalized treatments. 🧠 Fascinated by this cutting-edge research? Dr. Bonni Goldstein recently led a workshop where she shared practical guidance and breakthrough findings on using medicinal cannabis to treat autism. While emotions are still high from Dr. Goldstein's phenomenal workshop, the excitement continues! We are thrilled to announce another must-attend event on August 20, 2024: "Mastering Autism with Medicinal Cannabis." Dr. Goldstein is a true pioneer in her field, and this is a unique opportunity you won’t want to miss. 🗓 When: Tuesday, August 20, 2024 🕕 Time: 6:00 pm 👉 Register Now and be part of another groundbreaking discussion! https://lnkd.in/dpzp3rG2 Don’t miss out on learning such invaluable information—stay tuned for more updates and ensure you never miss out on the latest medical advancements. Join us and be part of the revolutionary discussions shaping the future of pediatric care. Let’s stay informed and explore new horizons in healthcare together! #MedicalCannabis #AutismResearch #SalivaDiagnostics #PediatricCare #BonniGoldstein #InnovativeTreatment #HealthcareRevolution #ASD #PersonalizedMedicine #FutureOfMedicine #BreakthroughResearch #MedicinalCannabisWorkshop #CuttingEdgeMedicine #AutismAwareness #HealthCareInnovations #medihuanna

Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial Efficacy of Esketamine for Prenatal Depression in Mothers Key Results and Practical Considerations Results: A single low dose of esketamine significantly reduced the prevalence of major depressive episodes at 42 days postpartum in mothers with prenatal depression when compared to a placebo. This represents a substantial reduction in postpartum depression risk. Additionally, esketamine led to lower depression scores on standardized tests at seven and 42 days postpartum. Adverse Events: The esketamine group experienced a higher incidence of neuropsychiatric adverse events, but these symptoms were short-lived and did not require drug intervention. Value: The study highlights the potential practical value of esketamine in reducing postpartum depression in mothers with prenatal depression, with manageable transient side effects. Future Application: This research offers potential insights for enhancing patient outcomes in clinical practice. Practical Solutions for Advancing Medical Practice Utilizing AI for Enhanced Clinical Workflows AI-Driven Platform: DocSym, our AI-driven platform, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians, facilitating informed decision-making. Streamlining Healthcare Operations with Mobile Apps Mobile Apps: Our mobile apps support scheduling, monitoring treatments, and telemedicine, simplifying patient care management and enabling digital service expansion. AI Integration: AI integration in clinics can optimize workflows, enhance patient outcomes, and reduce paperwork, fostering efficient and improved healthcare delivery. Learn more about how our solutions can support and advance medical practice at aidevmd.com. https://lnkd.in/gGvg48DY #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

Musk’s Neuralink Says Tiny Wires Of Brain Chip In First Patient Now Stable https://lnkd.in/d9Xk5Grj Social media medical advice: Do your research, ask medical experts, use discretion, say doctors https://lnkd.in/dAYaftjE SC for meeting of stakeholders to discuss quality, shortage of antiretroviral drugs for HIV patients https://lnkd.in/dPpVSA3j Pfizer moves forward with once-daily weight loss pill after scrapping earlier version https://lnkd.in/dSqYRibc Delhi HC bans Zydus' biosimilar Sigrima in a landmark injunction order https://lnkd.in/dnnvuJf7 Two quacks arrested, medical equipment seized https://lnkd.in/dSNGcNxS 12.07.2024 #doctor #doctors #hospital #hospitals #medicine #medicines #medicaleducation #medicalstudents #medicalstudent #Telehealth #Innovation #Technology #education #motivatio #economy #research n #inspiration #DeltaVariant #Covid19 #TrasmissibleVirus #covid #covid19protection #covid19vaccine #covid19vaccination #covid19pandemic #covid 19 #covid19news #covid19impact #covid19economy #covid19research #covid19insights #covid19safety' #medical #doctor #doctors #hospital #hospitals #medicine #medicines #medicaleducation #medicalstudents #medicalstudent #Telehealth #Innovation #Technology #education #motivatio #economy #research n #inspiration #DeltaVariant #Covid19 #TrasmissibleVirus #covid #covid19protection #covid19vaccine #covid19vaccination #covid19pandemic #covid 19 #covid19news #covid19impact #covid19economy #covid19research #covid19insights #covid19safety #leucorrhoea #UTI #Parenthood #IUD #IUD_FACTS #Dysmenorrhea #Menorrhagia #PCOS #Demystifying_Endometrial_polyps #Menorrhagia #Oligomenorrhea #Breast_cancer #PCOS #folicacid #gynecologiccancers #breastfeeding #PID #gyne #GynecologyClinic #gynecologist #gynecologyandobstetrics #bookappointment #menstrualhealth #menopausesupport #pregnancy #vaginalhealth #Dr_ILA_Gupta #mindset #positivity #fear #stressmanagement #tuberculosis #brain #radiology #mri #sequence #health #neurology #anatomy #infection

📃Scientific paper: Long-term social and professional outcomes in adults after pediatric kidney failure Abstract: Background Little is known about the long-term social and professional outcomes in adults after pediatric kidney replacement therapy (KRT). In this study, we described social and professional outcomes of adults after kidney failure during childhood and compared these outcomes with the general population. Methods We sent a questionnaire to 143 individuals registered in the Swiss Pediatric Renal Registry (SPRR) with KRT starting before the age of 18 years. In the questionnaire, we assessed social (partner relationship, living situation, having children) and professional (education, employment) outcomes. Logistic regression models adjusted for age at study and sex were used to compare outcomes with a representative sample of the Swiss general population and to identify socio-demographic and clinical characteristics associated with adverse outcomes. Results Our study included 80 patients (response rate 56%) with a mean age of 39 years (range 19–63). Compared to the general population, study participants were more likely to not have a partner (OR = 3.7, 95%CI 2.3–5.9), live alone (OR = 2.5, 95%CI 1.5–4.1), not have children (OR = 6.8, 95%CI 3.3–14.0), and be unemployed (OR = 3.9, 95%CI 1.8–8.6). No differences were found for educational achievement ( p  = 0.876). Participants on dialysis at time of study were more often unemployed compared to transplanted participants (OR = 5.0, 95%CI 1.2–21.4) and participants with > 1 kidney transplantation more often had a lower educa... Continued on ES/IODE ➡️ https://etcse.fr/0fqFw ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.